Home › Funds › Sofinnova Investments, Inc. › RARE
Sofinnova Investments, Inc. position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Sofinnova Investments, Inc. reported holding 500,000 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$16.7M, representing 0.89% of its reported portfolio and ranking #29 among its reported holdings. Sofinnova Investments, Inc. has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s RARE position evolved
Sofinnova Investments, Inc. first disclosed a stake in RARE in Q4 2025 at 83,300 shares (US$1.9M). The position peaked in Q2 2026 at 500,000 shares, worth US$16.7M. Across 3 filings, Sofinnova Investments, Inc. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 500,000 shares valued at US$16.7M — an increase of 150,000 shares quarter over quarter.. Notable position changes include a 320% increase in Q1 2026 (shares rose 59% over the following quarter), a 43% increase in Q2 2026 (shares fell 55% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 83.30K | $1.92M | New |
| Q1 2026 | 350.00K | $7.33M | Add |
| Q2 2026 | 500.00K | $16.70M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held RARE?
Sofinnova Investments, Inc. has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Sofinnova Investments, Inc.'s current position in RARE?
As of Q2 2026, Sofinnova Investments, Inc. holds 500.00K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $16.70M, representing 0.89% of its reported portfolio and ranking #29.
Has Sofinnova Investments, Inc. been buying or selling RARE?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in RARE. The position peaked in Q2 2026 at 500.00K shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.